Related Experiment Video
Updated: May 22, 2025
07:59
Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
Published on: April 4, 2022
1.2K
Management of angina pectoris
Riccardo Rinaldi1, Vijay Kunadian2, Filippo Crea3
1Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart, Rome, Italy; Cardiology Unit, Infermi Hospital, Rimini, Italy.
Trends in Cardiovascular Medicine
|March 14, 2025
Summary
Recent advancements in angina management focus on personalized care, integrating medication, interventions, and lifestyle changes for better outcomes in ischemic heart disease. Tailored strategies are key for both obstructive and non-obstructive coronary artery disease.
Area of Science:
- Cardiology
- Internal Medicine
- Clinical Research
Background:
- Angina pectoris, a key symptom of ischemic heart disease, presents a substantial global health and economic challenge.
- Effective management requires a comprehensive, patient-centered approach to mitigate cardiovascular risk and enhance quality of life.
Purpose of the Study:
- To review recent advancements in angina management strategies.
- To emphasize a personalized, integrated approach combining pharmacological, interventional, and lifestyle modifications.
- To discuss emerging therapies and future directions in optimizing patient outcomes.
Main Methods:
- Review of current literature on angina management.
- Analysis of treatment strategies for obstructive coronary artery disease (CAD) and angina/ischemia with non-obstructive coronary arteries (ANOCA/INOCA).
- Evaluation of lifestyle interventions, emerging therapies, and technological advancements.
Main Results:
- Optimal medical therapy is foundational for obstructive CAD, requiring individualized treatment plans.
- Precise endotype classification is crucial for ANOCA/INOCA, enabling tailored therapeutic strategies.
- Lifestyle interventions and structured exercise significantly improve cardiovascular outcomes and functional capacity.
Conclusions:
- Personalized management integrating medical, interventional, and lifestyle strategies is essential for angina.
- Emerging therapies and technologies offer new hope for refractory cases and ANOCA/INOCA.
- Future research should focus on precision medicine, digital health, and multidisciplinary care for advanced angina management.
Related Concept Videos
01:16Antianginal Drugs: Nitrates and β-Blockers
485
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
485
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
432
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
432
01:26Peptic Ulcer Disease IV: Management
56
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
56
01:17Increased pulse rate
634
Tachycardia is a condition marked by an abnormally fast or irregular heart rate, surpassing the typical resting rate. In adults, tachycardia is characterized by a pulse rate ranging from 100 to 180 beats per minute. The increased heart rate can result in inadequate blood flow to various body parts, ultimately diminishing the oxygen supply to organs and tissues.
Many factors can elevate the risk of developing tachycardia. These include advanced age, a family history of arrhythmias, and an...
Many factors can elevate the risk of developing tachycardia. These include advanced age, a family history of arrhythmias, and an...
634
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
126
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
126
01:17Ischemic Heart Disease: Overview
1.1K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.1K